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What do we learn from this article? 
A combination therapy of gemcitabine with docetaxel seems to be a good treatment 
regime for Leiomyosarcoma metastasis. 
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Sir,  
Leiomyosarcoma is a type of soft tissue sarcoma which is a very tumor found in the 
human mankind [1]. It is predominantly localized either in stomach, small intestine or 
retroperitoneum [2] and often metastasizes to the distant parts like the lungs or liver. 
The main route of the metastasis is via the bloodstream, however, the lymphatics 
could also be used as a medium. The etiology of leiomyosarcoma (LMS) is yet 
unknown to men, but few studies has shown that genetic factors have an important 
role to play [1]. The treatment options available for LMS metastasis (mets) in liver are 
very limited which ranges from chemotherapy, radiofrequency ablation and target 
therapy. Here I discuss a case of LMS mets to the liver managed by a combination 
therapy of Gemcitabine and Docetaxel. 
A 47 year old patient came to the hospital having a mets of LMS to the liver (primary 
LMS was in stomach which was resected 2 years back). Post resection of the primary 
tumor from the stomach, the patient was put on doxorubicin (6 cycles) as a 
precautionary treatment. However, two years after I noticed mets (one large lesion 
of approximately 29x27 mm in right lobe and other small multiple lesions) in the liver. 
The patient was then once again put on Doxorubicin (2 cycles). However, the 
treatment did not work and the size of the largest lesion increased to 35x24 mm with 
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an increment in the number of other lesions. Post the 
primary doxorubicin treatment, the patient was given 3 
cycles of D-gemcitabine (1400mg) on day 1 followed by a 
combination of gemcitabine (1200 mg) with docetaxel 
(100mg) on day 8. Following this regimen, there was a 
considerable reduction in the number and size of other 
lesions/masses in the liver seen in USG. The patient was 
again put on 2 more cycles of the same regime and further 
there was a reduction in the size and number of lesions. Now 
the largest lesion had a size of only 24x23 mm.  
Reduction in masses showed a ray of hope and the patient 
is again advised to undergo 2 more cycles of the same 
regime. Further, depending upon the condition of other 
lesions, radiofrequency ablation may be a viable option. 
Hence I suggest that more research should be done on this 
topic and more chemotherapeutic options should be 
available. Till then, a combination therapy of gemcitabine 
with docetaxel seems a good treatment regime for LMS 
mets. 
References 
1. Leiomyosarcoma. National organization for rare 
disorders. Available from: 
https://rarediseases.org/rare-
diseases/leiomyosarcoma. Accessed on March 21st, 
2017. 
2. Piovanello P, Viola V, Costa G, Carletti M, Cecera A, 
Turchetta F, Iudicone R, Catalano G, Santucci A, 
Recchia F, Fiorillo L. Locally advanced 
leiomyosarcoma of the spleen. A case report and 
review of the literature. World journal of surgical 
oncology. 2007;5(1):135. 
